Tri-Linyah

Acne Vulgaris, moderate Vulvovaginal atrophy, Hot flashes + 9 more

Treatment

9 FDA approvals

20 Active Studies for Tri-Linyah

What is Tri-Linyah

Norgestimate

The Generic name of this drug

Treatment Summary

Ethinylestradiol is a synthetic form of the hormone estrogen that was first developed in 1938. It was designed to be more easily absorbed when taken orally than other forms of estrogen. As a result, it soon became the main form of estrogen used in contraceptive pills. Ethinylestradiol was approved by the FDA in 1943 and is still widely used today.

Ortho Tri Cyclen

is the brand name

image of different drug pills on a surface

Tri-Linyah Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Ortho Tri Cyclen

Norgestimate

1989

113

Approved as Treatment by the FDA

Norgestimate, commonly known as Ortho Tri Cyclen, is approved by the FDA for 9 uses which include Postmenopausal Osteoporosis and severe menopausal vulvovaginal atrophy .

Postmenopausal Osteoporosis

Used to treat Postmenopausal Osteoporosis in combination with Estradiol

severe menopausal vulvovaginal atrophy

Used to treat severe menopausal vulvovaginal atrophy in combination with Estradiol

Oral Contraceptives

Used to treat Oral Contraceptives in combination with Ethinylestradiol

Acne Vulgaris

Used to treat moderate Acne vulgaris in combination with Ethinylestradiol

Osteoporosis, Postmenopausal

Used to treat Postmenopausal Osteoporosis in combination with Estradiol

moderate Vulvovaginal atrophy

Used to treat moderate Vulvovaginal atrophy in combination with Estradiol

Hot flashes

Used to treat Menopause in combination with Estradiol

moderate Menopausal Vasomotor Symptoms

Used to treat moderate Menopausal Vasomotor Symptoms in combination with Estradiol

Menopause

Used to treat severe Vasomotor Symptoms Associated With Menopause in combination with Estradiol

Effectiveness

How Tri-Linyah Affects Patients

Ethinylestradiol is a synthetic hormone that helps to prevent ovulation and reduce the growth of the lining of the womb. It is taken once daily and is considered to be a safe drug. However, patients should be aware that there is a risk of blood clots occurring when taking this medication.

How Tri-Linyah works in the body

Ethinylestradiol is a synthetic form of estrogen. Taking it can help reduce the chance of pregnancy by stopping ovulation, making it harder for sperm to travel, and preventing changes in the uterus. It also reduces luteinizing hormone and increases sex hormone binding globulin. All of these effects make it harder for a fertilized egg to implant in the uterus.

When to interrupt dosage

The amount of Tri-Linyah is contingent upon the diagnosed affliction, including Acne Vulgaris, Hormonal Contraception and Folate supplementation therapy. The degree of dosage shifts as per the delivery approach featured in the table beneath.

Condition

Dosage

Administration

Polycystic Ovarian Syndrome

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

moderate Vulvovaginal atrophy

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

severe menopausal vulvovaginal atrophy

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Menopause

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Osteoporosis, Postmenopausal

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Oral Contraceptives

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Menorrhagia

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Hirsutism

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

moderate Menopausal Vasomotor Symptoms

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Hot flashes

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Acne Vulgaris

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Dysmenorrhea

, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg

Kit, , Oral, Tablet, Tablet - Oral, Kit - Oral

Warnings

Tri-Linyah Contraindications

Condition

Risk Level

Notes

Breast

Do Not Combine

Breast Cancer

Do Not Combine

high risk of arterial thrombotic disease

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Hypersensitivity

Do Not Combine

Venous Thrombosis

Do Not Combine

Pulse Frequency

Do Not Combine

estrogen-sensitive cancer

Do Not Combine

Metrorrhagia

Do Not Combine

Liver Neoplasms

Do Not Combine

There are 20 known major drug interactions with Tri-Linyah.

Common Tri-Linyah Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Norgestimate.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Norgestimate.

Alectinib

Major

The metabolism of Alectinib can be increased when combined with Norgestimate.

Aminophylline

Major

The metabolism of Aminophylline can be increased when combined with Norgestimate.

Astemizole

Major

The metabolism of Astemizole can be increased when combined with Norgestimate.

Tri-Linyah Toxicity & Overdose Risk

Women who overdose on birth control may experience irregular bleeding, nausea, vomiting, breast discomfort, abdominal pain, drowsiness, and exhaustion. Treatment of this overdose should include watching for changes in potassium and sodium levels, as well as signs of metabolic acidosis.

image of a doctor in a lab doing drug, clinical research

Tri-Linyah Novel Uses: Which Conditions Have a Clinical Trial Featuring Tri-Linyah?

38 active studies are currently being conducted to investigate the potential of Tri-Linyah as a therapeutic intervention for Folate supplementation therapy, Premenstrual Dysphoric Disorder and Menopause.

Condition

Clinical Trials

Trial Phases

Dysmenorrhea

1 Actively Recruiting

Not Applicable

Acne Vulgaris

0 Actively Recruiting

Osteoporosis, Postmenopausal

0 Actively Recruiting

Oral Contraceptives

1 Actively Recruiting

Not Applicable

Menopause

0 Actively Recruiting

Polycystic Ovarian Syndrome

7 Actively Recruiting

Not Applicable, Phase 1

moderate Menopausal Vasomotor Symptoms

0 Actively Recruiting

Hirsutism

0 Actively Recruiting

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3

moderate Vulvovaginal atrophy

0 Actively Recruiting

Menorrhagia

3 Actively Recruiting

Phase 1, Phase 2, Not Applicable

severe menopausal vulvovaginal atrophy

0 Actively Recruiting

Tri-Linyah Reviews: What are patients saying about Tri-Linyah?

5

Patient Review

4/15/2016

Tri-Linyah for Birth Control

I've been on this pill for almost 4 months now and haven't had a single side effect. All the reviews I read terrified me but I'm totally fine.

5

Patient Review

8/9/2019

Tri-Linyah for Absence of Menstrual Periods

I've been taking this birth control for nearly five years and I'm very pleased. My period is regular, my cramps aren't as bad, and it's helped clear up my acne significantly.

4.3

Patient Review

9/28/2018

Tri-Linyah for Birth Control

The only downside to this birth control that I've noticed is that it's given me acne. Other than that, it's been great! It's shortened and lightened my periods as well as reducing cramping. Unless something changes, I'll definitely keep taking it.

4.3

Patient Review

1/30/2019

Tri-Linyah for Birth Control

My acne has calmed down, but I've been spotting for more than two weeks now. It's frustrating because it feels like I'm on an endless period. I don't think I'll continue taking this birth control pill; it might work for others but not for my body.

4

Patient Review

2/7/2018

Tri-Linyah for Painful Periods

This treatment has made my periods much more bearable. I used to be in a lot of pain and now it's only for a day or so. I've also noticed that my skin is better. However, I am always very moody, nauseous, and have gained weight. My breasts have gone from a C cup to a double or triple D cup. I get migraines quite often too. The most frustrating part for me is the weight gain; I feel fat and ugly. I've gained about 17 pounds since starting this medication.

3.7

Patient Review

2/5/2017

Tri-Linyah for Birth Control

I've been on this medication for six months now and have noticed some very concerning changes in my mood and behavior. I'm also vomiting more frequently than before.

3.3

Patient Review

1/4/2018

Tri-Linyah for Birth Control

I've noticed an increase in my vaginal discharge since switching to this birth control, which is normal. However, it's more than I had before and can be a bit inconvenient.

3.3

Patient Review

9/28/2017

Tri-Linyah for Birth Control

I unfortunately found that this medication made my migraines worse and cramps more severe.

3

Patient Review

6/10/2018

Tri-Linyah for Birth Control

While this pill did prevent pregnancy, it was not worth the daily hunger, bloating, and spotting. My hormones were all over the place while I was taking this pill, and I would never recommend it to anyone.

2.7

Patient Review

2/25/2016

Tri-Linyah for Birth Control

While this medication did prevent pregnancy, I was definitely not a fan of the side effects. Bloating, anxiety, depression, mood swings, migraines and bad acne made me feel like I was undergoing puberty from hell. The upside is that my sex drive increased and my boobs got bigger.

2.7

Patient Review

8/8/2017

Tri-Linyah for Birth Control

I haven't become pregnant yet, but I find this birth control pill to have several negative side effects. The biggest issue is that I'm bleeding much more heavily and for longer periods of time. I've also had pretty severe cramping which radiates into my lower back. One month my period came early which is NOT supposed to happen on birth control, and this month it is still going 3 days after I have started the next pack. Overall, I would not suggest this product to others.

2

Patient Review

1/31/2017

Tri-Linyah for Birth Control

I'm pregnant with my fourth child because this medication didn't work for me.

1.7

Patient Review

5/3/2017

Tri-Linyah for Abnormally Long or Heavy Periods

I would not recommend this pill to anyone. It was supposed to help regulate my heavy periods but instead I bled for the entire two months I was on it. Plus, I had anxiety, nausea and vomiting, and insomnia. Once I stopped taking the pill, all of those symptoms went away.

1

Patient Review

11/3/2016

Tri-Linyah for Birth Control

I would not recommend this pill to anyone. It's made my acne so much worse and I've only been taking it for 1 1/2 months.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about tri-linyah

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does Tri-Linyah cause weight gain?

"While taking Tri-Linyah and other birth control pills, some women may experience weight gain. The hormones in the pills have a chance of giving the women the munchies; however, the weight gain is mostly from water retention and not actual fat."

Answered by AI

What are side effects of Tri-Linyah?

"If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

Nausea, vomiting, headache, bloating, breast tenderness, and weight change may occur. Vaginal bleeding may occur, especially during the first few months of use. If any of these effects persist or worsen, tell your doctor or pharmacist promptly."

Answered by AI

Is Tri-Linyah the same as Ortho Tri Cyclen?

"is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

ORTHO TRI-CYCLEN is a medication that is used to prevent pregnancy. It is a birth control pill that is taken by mouth."

Answered by AI

What kind of birth control is Tri-Linyah?

"Tri-Linyah is a combination oral contraceptive pill containing the progestational compound norgestimate and the estrogenic compound ethinyl estradiol."

Answered by AI

Clinical Trials for Tri-Linyah

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of Lindus Health - DECENTRALIZED STUDY in Boston, United States.

Neurostimulation for Heavy Menstrual Bleeding

14 - 45
Female
Boston, MA

The LUNA study is a prospective, randomized, double-blind, sham-controlled, decentralized clinical trial in participants with heavy menstrual bleeding of no known structural cause. The study includes two age-based cohorts: adolescents aged 14-21 and adults aged 22-45. Participants in both cohorts will be randomized to receive transcutaneous auricular neurostimulation (tAN), which targets the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN), or sham stimulation. Participants will be enrolled into the study over the course of five consecutive menstrual cycles. All study activities will occur remotely and in addition to participants' typical treatment for HMB (as allowed by the eligibility criteria). During the first two consecutive menstrual cycles (M1 - M2, "Baseline Phase"), no tAN treatment will be delivered. Participants will estimate blood loss using the Pictorial Bleeding Assessment Chart (PBAC), and menstrual cramp pain will be assessed with a Numerical Rating Scale (NRS), daily throughout the duration of the menstruation phase of their two baseline menstrual cycles. Menstrual symptoms will be assessed using the Cox Menstrual Symptom Scale (CMSS) and a general quality of life assessment will be conducted on the final day of menstruation using the RAND Short-Form 36 (RAND-36). Menstrual-related quality of life assessments will also be conducted on the final day of each menstruation using the Menstrual Bleeding Questionnaire (MBQ) in the adult cohort, and the adolescent version (aMBQ) in the adolescent cohort. During the following three consecutive menstruations (M3 - M5, "Treatment Phase"), participants will self-administer one 2-hour sham or active tAN session daily, beginning Day 1 of menstruation through the final day of menstruation in each menstrual cycle. Blood loss (via the PBAC) and menstrual cramp pain (via the NRS) will be assessed daily throughout the duration of each menstruation. Quality of life will be assessed with the CMSS, RAND-36, and the MBQ (adults) or aMBQ (adolescents) on the final day of each menstruation. A device usability survey will be completed at the end of M3 and M5. Participants will exit the study after the final day of M5.

Waitlist Available
Online Trial

Lindus Health - DECENTRALIZED STUDY

Navid Khodaparast, PhD

Spark Biomedical, Inc.

Image of Goldring Center for High Performance Sport in Toronto, Canada.

Menstrual Cycle vs. Birth Control Pills for Protein Metabolism

18 - 40
Female
Toronto, Canada

The muscles of the body are constantly breaking down old proteins and building new ones. These two processes, protein breakdown and protein synthesis, together are known as protein turnover. Protein turnover is essential for maintaining healthy muscle. Despite its importance, females have historically been underrepresented in protein metabolism research. A long-standing assumption has been that fluctuations in female sex hormones such as estrogen and progesterone, whether across the natural menstrual cycle or in individuals using oral contraceptives (OCs), make metabolism and training responses too variable to study. Because of this, many researchers have excluded female participants for logistical reasons. Resistance exercise, such as weightlifting, is the most effective way to increase muscle size and strength. Each resistance-training session triggers muscle protein synthesis (MPS), the process by which new muscle proteins are built. Consuming dietary protein or individual amino acids further increases the rate at which new proteins are formed. Over time, higher rates of protein synthesis support muscle growth and the maintenance of other lean tissues in the body. The purpose of this study is to examine how menstrual cycle phases and OC use influence the synthesis of proteins in both muscle tissue and the rest of the body. Improving scientific understanding in this area will support more effective, evidence-based training and nutrition recommendations for females.

Recruiting
Has No Placebo

Goldring Center for High Performance Sport

Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada

The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.

Phase 4
Recruiting

Erevna Innovations Inc.

Andreas Nikolis, MD, PhD

Have you considered Tri-Linyah clinical trials?

We made a collection of clinical trials featuring Tri-Linyah, we think they might fit your search criteria.
Go to Trials
Image of Center for Human Nutrition in Fayetteville, United States.

Protein Meals for Polycystic Ovary Syndrome

18 - 50
Female
Fayetteville, AR

Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by insulin resistance, hyperandrogenism, and reproductive dysfunction. Dietary strategies that improve postprandial insulin and glucose responses are central to managing metabolic symptoms in PCOS. Meals higher in protein can attenuate postprandial glycemia and enhance satiety, but the effects may vary by protein source. Animal sources of protein typically have higher essential amino acid content and insulinogenic potential, whereas plant proteins offer fiber and phytochemicals that may influence glycemic dynamics differently. Few studies have directly compared the acute metabolic effects of plant versus animal protein in women with PCOS. Given the distinct pathophysiology of PCOS, extrapolating findings from healthy populations may be misleading. Understanding protein-specific effects on postprandial insulin, glucose, and appetite-regulating hormones in this group is essential for targeted nutrition guidance. Additionally, plant-based diets are increasingly promoted for cardiometabolic health, but their acute effects in insulin-resistant women remain underexplored. This study will assess whether plant and animal protein meals elicit differential postprandial responses in women with PCOS. Findings may inform dietary recommendations aimed at improving metabolic outcomes in this high-risk population.

Recruiting
Has No Placebo

Center for Human Nutrition

Jamie I Baum, PhD

Image of William J. Hybl Sports Medicine and Performance Center in Colorado Springs, United States.

Moderate Aerobic Exercise for Menstrual Symptoms

18 - 40
Female
Colorado Springs, CO

The goal of this clinical trial is to evaluate the impact of moderate aerobic exercise on menstrual symptom management in sedentary women both using and not using hormonal contraceptives. The main questions it aims to answer are: Is there a reduction in physical and/or psychological menstrual cycle related symptom burden with participation in moderate aerobic exercise for sedentary women using and not using hormonal contraceptives? Is there a difference in physical and/or psychological menstrual cycle related symptom burden between hormonal contraceptive and non-hormonal contraceptive users? Is a moderate aerobic exercise intervention more effective in reducing physical and/or psychological menstrual related symptom burden for sedentary women using or not using hormonal contraceptives? Participants will: * Have their body composition assessed using dual energy X-ray absorptiometry pre and post exercise intervention. * Complete a Menstrual Symptom Index (MSi) to report daily menstrual cycle related symptom burden in addition to the Premenstrual Symptom Screening Tool (PSST) and Heavy Menstrual Bleeding (HMB) questionnaire monthly. * Utilize an at-home monitor to test urinary luteinizing hormone, estrone-3-glucuronide, and pregnanediol glucuronide approximately 10 times per month and report menstrual cycle length. * Record physical activity habits by continuously wearing a wrist-based accelerometer and chest-strap heart rate monitor during planned aerobic exercise sessions and complete the International Physical Activity Questionnaire (IPAQ) monthly. * Maintain their usual sedentary activity habits for one menstrual cycle followed by completion of an exercise intervention designed to progress individuals to meet minimum recommended aerobic physical activity guidelines of 150 minutes per week set by the American College of Sports Medicine for two menstrual cycles.

Recruiting
Has No Placebo

William J. Hybl Sports Medicine and Performance Center

Have you considered Tri-Linyah clinical trials?

We made a collection of clinical trials featuring Tri-Linyah, we think they might fit your search criteria.
Go to Trials
Image of Noll Laboratory in University Park, United States.

Estradiol and Elagolix for Menopause

42 - 64
Female
University Park, PA

The frequency and severity of heat waves has increased in the last decades. Older adults (over 65 years) have impaired responses to heat stress making them at increased risk for adverse events. Previous heat waves report that women over 65 experience worse health outcomes than any other age group and age matched men. Aging and reproductive hormones, specifically estrogen, independently alter responses to heat stress. However, the combined effects of low estrogen following menopause and aging on the response to heat stress are unknown. In this study, the investigators will identify the role of estrogen in pre and post menopausal women on thermoregulatory responses to heat stress.

Phase 4
Recruiting

Noll Laboratory

W. Larry Kenney, Ph.D.

Have you considered Tri-Linyah clinical trials?

We made a collection of clinical trials featuring Tri-Linyah, we think they might fit your search criteria.
Go to Trials